Cross-source evidence timeline

Dalbavancin research timeline

Follow 46 selected, directly cited source records from October 12, 2009 through October 10, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

46Selected records
12Source years
3Evidence lanes
October 10, 2026Latest source date

Source year

2026

11 records
  1. Literature metadata

    Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.↗

    PubMed lists PMID 34931283 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2021-12-21 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT06810583↗

    PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

  3. Literature metadata

    Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.↗

    PubMed lists PMID 41892415 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-03-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Federal Register notice 2026-15149↗

    The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT05046860↗

    PeptideScanner retained ClinicalTrials.gov record NCT05046860 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-06-22, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

  6. Regulatory

    Drugs@FDA application ANDA219604↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.↗

  7. Literature metadata

    [Translated article] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections.↗

    PubMed lists PMID 40993014 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Systematic Review, Journal Article, with publication-date metadata of 2025-09-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Regulatory

    Drugs@FDA application ANDA218602↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗

  9. Literature metadata

    Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.↗

    PubMed lists PMID 32603683 in International journal of antimicrobial agents as Journal Article, Systematic Review, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review.↗

    PubMed lists PMID 32629114 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-03 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    The current and future off-label uses of dalbavancin: a narrative review.↗

    PubMed lists PMID 36808371 in European review for medical and pharmacological sciences as Review, Journal Article, with publication-date metadata of 2023-02 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

5 records
  1. Regulatory

    Drugs@FDA application ANDA218929↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA217591↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.↗

  3. Regulatory

    Drugs@FDA application ANDA219465↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.↗

  4. Literature metadata

    Dalbavancin for the treatment of bone and joint infections: A meta-analysis.↗

    PubMed lists PMID 39029624 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients.↗

    PubMed lists PMID 40001365 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-01-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02814916↗

    PeptideScanner retained ClinicalTrials.gov record NCT02814916 at 2026-11-16T17:37:42.807Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

  2. Literature metadata

    Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review.↗

    PubMed lists PMID 38533780 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Letter, Review, with publication-date metadata of 2024-03-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.↗

    PubMed lists PMID 38449918 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2024-02-07 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

3 records
  1. Literature metadata

    A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.↗

    PubMed lists PMID 37887193 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-09-28 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Dalbavancin in Bone and Joint Infections: A Systematic Review.↗

    PubMed lists PMID 37513919 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-07-15 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Global trends of dalbavancin: A bibliometric analysis.↗

    PubMed lists PMID 35735062 in Journal of clinical pharmacy and therapeutics as Journal Article, Review, with publication-date metadata of 2022-06-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2022

3 records
  1. Literature metadata

    Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.↗

    PubMed lists PMID 35353020 in Expert review of anti-infective therapy as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-04-08 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT04959799↗

    PeptideScanner retained ClinicalTrials.gov record NCT04959799 at 2026-11-16T17:37:42.807Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

  3. Literature metadata

    Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review.↗

    PubMed lists PMID 34923922 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2021-12-19 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2021

7 records
  1. Literature metadata

    Dalbavancin.↗

    PubMed lists PMID 34598419 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Journal Article, Review, with publication-date metadata of 2021-09-30 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.↗

    PubMed lists PMID 34072670 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-05-31 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.↗

    PubMed lists PMID 33962065 in Journal of global antimicrobial resistance as Journal Article, Review, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Dalbavancin for the management of osteomyelitis: a major step forward?↗

    PubMed lists PMID 32457989 in The Journal of antimicrobial chemotherapy as Journal Article, Review, with publication-date metadata of 2020-10-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis.↗

    PubMed lists PMID 31087630 in Clinical pharmacology in drug development as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-14 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Current trends in the real-life use of dalbavancin: report of a study panel.↗

    PubMed lists PMID 32721599 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).↗

    PubMed lists PMID 32223465 in Expert review of anti-infective therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2020-03-29 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02961764↗

    PeptideScanner retained ClinicalTrials.gov record NCT02961764 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-04-10, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03233438↗

    PeptideScanner retained ClinicalTrials.gov record NCT03233438 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-01-18, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

Source year

2019

3 records
  1. Literature metadata

    The role of dalbavancin in skin and soft tissue infections.↗

    PubMed lists PMID 29298166 in Current opinion in infectious diseases as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Regulatory

    Federal Register notice 2019-09007↗

    The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT02685033↗

    PeptideScanner retained ClinicalTrials.gov record NCT02685033 at 2026-11-16T17:37:42.807Z. Its registry update date was 2019-01-04, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

Source year

2018

4 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02127970↗

    PeptideScanner retained ClinicalTrials.gov record NCT02127970 at 2026-11-16T17:37:42.807Z. Its registry update date was 2018-09-28, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

  2. Literature metadata

    The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery.↗

    PubMed lists PMID 29168673 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2017-11-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.↗

    PubMed lists PMID 29258361 in Expert opinion on drug metabolism & toxicology as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-12-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Federal Register notice 2018-02768↗

    The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

Source year

2015

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT01946568↗

    PeptideScanner retained ClinicalTrials.gov record NCT01946568 at 2026-11-16T17:37:42.807Z. Its registry update date was 2015-06-23, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

Source year

2014

3 records
  1. Regulatory

    Drugs@FDA application NDA021883↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.↗

  2. Regulatory

    Federal Register notice 2014-02942↗

    The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01339091↗

    PeptideScanner retained ClinicalTrials.gov record NCT01339091 at 2026-11-16T17:37:42.807Z. Its registry update date was 2014-01-31, and PeptideScanner's reviewed identity mapping was dalbavancin.↗

Source year

2009

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00678106↗

    PeptideScanner retained ClinicalTrials.gov record NCT00678106 at 2026-11-16T17:37:42.807Z. Its registry update date was 2009-10-12, and PeptideScanner's reviewed identity mapping was dalbavancin.↗